PubRank

Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Clinical Trial ID NCT01470794

PubWeight™ 20.26‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01470794

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2013 1.72
2 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
3 Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2011 1.22
4 Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012 1.05
5 Glioma virus therapies between bench and bedside. Neuro Oncol 2014 0.95
6 Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol 2015 0.94
7 What next for newly diagnosed glioblastoma? Future Oncol 2015 0.94
8 Current status of gene therapy for brain tumors. Transl Res 2012 0.90
9 EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future 2016 0.84
10 Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model. Cancer Gene Ther 2013 0.84
11 Gene therapy for malignant glioma. Mol Cell Ther 2014 0.83
12 Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 2015 0.83
13 Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Ther 2014 0.81
14 Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 2015 0.81
15 Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity. J Virol 2014 0.81
16 MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response. Hum Gene Ther 2014 0.80
17 Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther 2015 0.79
18 Gene-directed enzyme prodrug therapy. AAPS J 2014 0.77
19 Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. Hum Gene Ther Methods 2015 0.76
20 Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene. Hum Gene Ther Methods 2016 0.76
21 Combining cellular and gene therapy approaches for treatment of intracranial tumors. Oncoimmunology 2013 0.75
22 High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol 2016 0.75
23 Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Mol Ther Methods Clin Dev 2014 0.75
24 Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. Neuro Oncol 2016 0.75
Next 100